Microneedles for controlled and sustained intraocular drug delivery

Abstract Microneedles (MNs) have emerged as a promising technology for minimally invasive drug delivery, offering significant advantages in the treatment of ocular diseases. These miniaturized needles enable precise, localized drug delivery directly into specific tissues of the eye, such as the corn...

Full description

Saved in:
Bibliographic Details
Main Authors: Junsang Lee, Jinheon Jeong, Van Phuc Nguyen, Seokkyoon Hong, Yannis M. Paulus, Chi Hwan Lee
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:NPG Asia Materials
Online Access:https://doi.org/10.1038/s41427-025-00614-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849226157363298304
author Junsang Lee
Jinheon Jeong
Van Phuc Nguyen
Seokkyoon Hong
Yannis M. Paulus
Chi Hwan Lee
author_facet Junsang Lee
Jinheon Jeong
Van Phuc Nguyen
Seokkyoon Hong
Yannis M. Paulus
Chi Hwan Lee
author_sort Junsang Lee
collection DOAJ
description Abstract Microneedles (MNs) have emerged as a promising technology for minimally invasive drug delivery, offering significant advantages in the treatment of ocular diseases. These miniaturized needles enable precise, localized drug delivery directly into specific tissues of the eye, such as the cornea, sclera, vitreous, or retina, while minimizing pain and discomfort. MNs can be fabricated from various biocompatible materials, including metals, silicon, and biodegradable polymers, making them highly adaptable to various clinical applications. Recent advancements in MN design include the integration of 3D printing technologies to create highly customized geometries for improved drug delivery precision, the use of smart materials that enable stimuli-responsive and sustained drug release, and the development of hybrid microneedles combining different polymers to enhance both mechanical strength and controlled drug release. These innovations have established MNs as a superior alternative to traditional methods like eye drops or intravitreal injections, which often face issues of limited bioavailability and patient compliance. This review summarizes the current state of research on MN-based ocular drug delivery, focusing on material developments, fabrication methods, drug release mechanisms, and implantation techniques. Future directions for MN technology in ophthalmology are also discussed, highlighting its potential to improve treatment outcomes for complex ocular diseases.
format Article
id doaj-art-b005dc74759a4d19a3729cf7f8bc6e46
institution Kabale University
issn 1884-4057
language English
publishDate 2025-08-01
publisher Nature Portfolio
record_format Article
series NPG Asia Materials
spelling doaj-art-b005dc74759a4d19a3729cf7f8bc6e462025-08-24T11:35:59ZengNature PortfolioNPG Asia Materials1884-40572025-08-0117112610.1038/s41427-025-00614-7Microneedles for controlled and sustained intraocular drug deliveryJunsang Lee0Jinheon Jeong1Van Phuc Nguyen2Seokkyoon Hong3Yannis M. Paulus4Chi Hwan Lee5Weldon School of Biomedical Engineering, Purdue UniversityWeldon School of Biomedical Engineering, Purdue UniversityDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins UniversityWeldon School of Biomedical Engineering, Purdue UniversityDepartment of Ophthalmology, Wilmer Eye Institute, Johns Hopkins UniversityWeldon School of Biomedical Engineering, Purdue UniversityAbstract Microneedles (MNs) have emerged as a promising technology for minimally invasive drug delivery, offering significant advantages in the treatment of ocular diseases. These miniaturized needles enable precise, localized drug delivery directly into specific tissues of the eye, such as the cornea, sclera, vitreous, or retina, while minimizing pain and discomfort. MNs can be fabricated from various biocompatible materials, including metals, silicon, and biodegradable polymers, making them highly adaptable to various clinical applications. Recent advancements in MN design include the integration of 3D printing technologies to create highly customized geometries for improved drug delivery precision, the use of smart materials that enable stimuli-responsive and sustained drug release, and the development of hybrid microneedles combining different polymers to enhance both mechanical strength and controlled drug release. These innovations have established MNs as a superior alternative to traditional methods like eye drops or intravitreal injections, which often face issues of limited bioavailability and patient compliance. This review summarizes the current state of research on MN-based ocular drug delivery, focusing on material developments, fabrication methods, drug release mechanisms, and implantation techniques. Future directions for MN technology in ophthalmology are also discussed, highlighting its potential to improve treatment outcomes for complex ocular diseases.https://doi.org/10.1038/s41427-025-00614-7
spellingShingle Junsang Lee
Jinheon Jeong
Van Phuc Nguyen
Seokkyoon Hong
Yannis M. Paulus
Chi Hwan Lee
Microneedles for controlled and sustained intraocular drug delivery
NPG Asia Materials
title Microneedles for controlled and sustained intraocular drug delivery
title_full Microneedles for controlled and sustained intraocular drug delivery
title_fullStr Microneedles for controlled and sustained intraocular drug delivery
title_full_unstemmed Microneedles for controlled and sustained intraocular drug delivery
title_short Microneedles for controlled and sustained intraocular drug delivery
title_sort microneedles for controlled and sustained intraocular drug delivery
url https://doi.org/10.1038/s41427-025-00614-7
work_keys_str_mv AT junsanglee microneedlesforcontrolledandsustainedintraoculardrugdelivery
AT jinheonjeong microneedlesforcontrolledandsustainedintraoculardrugdelivery
AT vanphucnguyen microneedlesforcontrolledandsustainedintraoculardrugdelivery
AT seokkyoonhong microneedlesforcontrolledandsustainedintraoculardrugdelivery
AT yannismpaulus microneedlesforcontrolledandsustainedintraoculardrugdelivery
AT chihwanlee microneedlesforcontrolledandsustainedintraoculardrugdelivery